Atomo Diagnostics Ltd (AT1) - Total Liabilities

Latest as of December 2025: AU$2.84 Million AUD ≈ $2.01 Million USD

Based on the latest financial reports, Atomo Diagnostics Ltd (AT1) has total liabilities worth AU$2.84 Million AUD (≈ $2.01 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Atomo Diagnostics Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Atomo Diagnostics Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how Atomo Diagnostics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Atomo Diagnostics Ltd.

Atomo Diagnostics Ltd Competitors by Total Liabilities

The table below lists competitors of Atomo Diagnostics Ltd ranked by their total liabilities.

Company Country Total Liabilities
S&W Corporation
KQ:103230
Korea ₩33.02 Billion
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
France €19.91 Million
RE Royalties Ltd
V:RE
Canada CA$45.99 Million
Solarmax Technology Inc. Common Stock
NASDAQ:SMXT
USA $117.60 Million
Big Rock Brewery Inc.
TO:BR
Canada CA$25.70 Million
Rewardle Holdings Ltd
AU:RXH
Australia AU$10.12 Million
Connexion Mobility Ltd
AU:CXZ
Australia AU$1.49 Million
Emerge Commerce Ltd
V:ECOM
Canada CA$18.71 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Atomo Diagnostics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Atomo Diagnostics Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.78 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Atomo Diagnostics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Atomo Diagnostics Ltd (2017–2025)

The table below shows the annual total liabilities of Atomo Diagnostics Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-06-30 AU$2.30 Million
≈ $1.63 Million
+77.81%
2024-06-30 AU$1.29 Million
≈ $915.87K
-23.11%
2023-06-30 AU$1.68 Million
≈ $1.19 Million
-6.90%
2022-06-30 AU$1.81 Million
≈ $1.28 Million
-15.96%
2021-06-30 AU$2.15 Million
≈ $1.52 Million
+32.80%
2020-06-30 AU$1.62 Million
≈ $1.15 Million
-85.94%
2019-06-30 AU$11.52 Million
≈ $8.15 Million
-8.88%
2018-06-30 AU$12.64 Million
≈ $8.95 Million
+6.97%
2017-06-30 AU$11.82 Million
≈ $8.36 Million
--

About Atomo Diagnostics Ltd

AU:AT1 Australia Medical Devices
Market Cap
$10.85 Million
AU$15.34 Million AUD
Market Cap Rank
#26953 Global
#1264 in Australia
Share Price
AU$0.02
Change (1 day)
-5.56%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.57
About

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.